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Abstract
Background: Baicalin has been reported to have anti-fibrosis effect; however, its mechanism still remains to be
elucidated. Adenosine A2a receptor (A2aR) is a novel inflammation regulator, and transforming growth factor-β1
(TGF-β1)-induced extracellular signal regulated kinase1/2 (ERK1/2) signaling pathway plays an important role in
idiopathic pulmonary fibrosis (IPF). This study was to explore the relationship of A2aR and TGF-β1-induced ERK1/2
in bleomycin (BLM)-induced pulmonary fibrosis in mice, and to investigate whether A2aR mediate the anti-fibrosis
effect of Baicalin on BLM-induced pulmonary fibrosis.
Methods: The A2aR−/− and A2aR+/+ mice were respectively divided into three groups: control group, model
group, baicalin group. Pulmonary fibrosis was induced in mice of model groups by intratracheal instillation of
bleomycin, and baicalin was administered in mice of baicalin groups daily for 28 days. Histopathological and
ultrastructural changes of lung tissues were evaluated. Lung coefficient and the levels of hydroxyproline (HYP) in lung
tissues were measured at the same time. The levels of serum TGF-β1 were measured by ELISA. The expression of
TGF-β1, ERK1/2, p-ERK1/2 and A2aR were detected by western blot and immunohistochemical staining techniques.
Results: Severe lung fibrosis was observed in the bleomycin-treated mice on day 28. The histopathological findings
and collagen content of lung tissues were much severer/higher in A2aR−/− mice than in A2aR+/+ mice. We also
showed that TGF-β1 and p-ERK1/2 were upregulated in bleomycin-treated mice and expressed higher in A2aR−/− mice
compared to A2aR+/+ mice. Besides, bleomycin-treated A2aR+/+ mice had increased A2aR level in lungs. However,
long-term treatment with baicalin in A2aR−/− and A2aR+/+ mice significantly ameliorated the histopathological changes
in lungs. Moreover, Increased TGF-β1 and p-ERK1/2 expressions in bleomycin-treated A2aR−/− and A2aR+/+ mice were
obviously diminished by baicalin. The baicalin-treated A2aR−/− mice had severer lung fibrosis and higher expressions of
TGF-β1 and p-ERK1/2 than A2aR+/+ mice. Baicalin has also upregulated the expression of A2aR in A2aR+/+ mice.
Conclusions: Genetic inactivation of A2aR exacerbated the pathological processes of bleomycin-induced pulmonary
fibrosis. Together, baicalin could inhibit BLM-induced pulmonary fibrosis by upregulating A2aR, suggesting A2aR as a
therapeutic target of baicalin for the treatment of pulmonary fibrosis.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic progres-
sive interstitial lung disorder with poor prognosis [1]. It’s
characterized by the proliferation of fibroblasts and de-
position of extracellular matrix (ECM) proteins, which
causes distorted lung architecture and function as well
as makes breathing increasing difficult, and finally leads
to respiratory failure [2, 3]. Over 5 million people world-
wide are affected by IPF with a mean survival time of
nearly 3 years [4]. But the mechanism of this disease is
still unclear. It includes various pathogenesis, such as in-
flammation, immune mechanisms, epithelial mesenchy-
mal transition (EMT) and oxidative stress [3, 5–7].
Therefore, no medication can effectively cure this dis-
ease and alternative approaches for this unmet medical
need are of interest.
Adenosine is an endogenous intracellular purine nu-
cleoside [8]. It exerts various physiological effects by
engaging different high-affinity adenosine receptors,
among which A2aR is an anti-inflammatory adenosine
receptor [9]. A2aR plays a protective role in a variety of
diseases. It is reported that activation of A2aR led to at-
tenuation of pulmonary hypertension and lung injury
[10, 11]. What’s more, Pharmacology study showed that
A2aR agonist, CGS21680 could effectively inhibit lung
inflammation that may lead to fibrosis [12], which
proves evidence that A2aR, as an endogenous protective
factor, plays an important role in inhibiting pulmonary
fibrosis.
TGF-β1 is one of the cytokines and plays a significant
part in regulating inflammation, cell growth and tissue
fibrosis [13]. Moreover, TGF-β1 plays a very important
role in the proliferation of lung fibroblasts and promotes
the production of ECM. TGF-β1 induces alveolar epithe-
lial to mesenchymal transition and stimulates alveolar
epithelial cells (AECs) to convert into myofibroblasts
[14], which was the probable mechanism of pulmonary
fibrosis (PF). ERK, a member of Mitogen-activated pro-
tein kinase (MAPK) superfamily, includes two subtypes:
ERK1 and ERK2. They play an important role in the
process of cell proliferation and differentiation by regu-
lating the expression of inflammatory mediators and cy-
tokines [15]. In recent years, some evidence has shown
that the ERK1/2 signaling pathway has a close link with
the TGF-β1 in rat or human lung fibroblasts [16, 17]. It
has been reported that EMT is also the pathogenesis of
renal interstitial fibrosis, and A2aR activation attenuated
the expression of profibrotic mediators TGF-β1 in renal
[18]. Therefore, we hypothesize that the knockout of
A2aR may aggravate pathological changes of PF by syn-
thesising of ECM via up-regulating TGF-β1 and ERK1/2.
Conversely, activation of A2aR may suppress the exacer-
bation of PF, suggesting that stimulation of A2aR might
exert significant protective effect on PF.
Baicalin is a flavonoid compound purified from Scutel-
laria baicalensis with a wide variety of anti-oxidative,
anti-inflammatory, anti-infection and anti-tumor func-
tions [19–22]. As a traditional Chinese medicine with
high value and widespread efficacy, baicalin has been
used in applications of pulmonary arterial hypertension
(PAH), hepatic cancer, acute lymphocytic leukemia, and
so on [22–24]. A recent study showed that baicalin sup-
pressed the hepatic fibrosis-induced increase in TGF-β1
levels [25]. Although baicalin has been found to exerted
therapeutic effects on rats with lung fibrosis induced by
bleomycin and to inhibit fibrosis through multiple path-
ways [26], there are only few reports concerning the
mechanism of baicalin on PF.
In this research, we aimed to explore the essential role
of adenosine A2a receptor in a BLM-induced pulmonary
fibrosis model using the A2aR KO mice, and investigated
whether baicalin protected against pulmonary fibrosis
via the TGF-β1-induced ERK1/2 signaling pathway.
Methods
Reagents
Baicalin was obtained from Sigma (St. Louis, MO, USA)
and dissolved in dimethyl sulfoxide, then diluted by ster-
ile saline. Bleomycin hydrochloride was obtained from
Nippon Kayaku (Co, Tokyo, Japan). Hydroxyproline
(HYP) assay kits were obtained from Nanjing Jiancheng
Biochemical Institute (Nanjing, China). Mouse TGF-β1
enzyme linked immunosorbent assay (ELISA) kit was
purchased from R&D (Minneapolis, MN, USA). The
rabbit antibodies against ERK1/2, phospho-ERK1/2,
and GAPDH were purchased from Cell Signaling Tech-
nology (Beverly, MA, USA). The mouse antibodies
against TGF-β1 and A2aR were purchased from Abcam
(Cambridge, UK). Peroxidase conjugated goat anti-
rabbit immunoglobulin G (IgG) and Peroxidase conju-
gated goat anti-mouse immunoglobulin G (IgG) was
purchased by Boster (Wuhan, China). DAB kit and
Polink-2 plus Polymer HRP Detection System were pro-
vided by ZSGB BIO (Beijing, China). SuperSignal (R)
West Femto Maximum Sensitivity Substrate and BCA
Protein Assay kit were provided by Thermo Fisher
Scientific (Waltham, MA, USA).
Animals
The A2aR knockout mice were purchased from the Jackson
laboratory and were established on the Balb/c strain
background. Wild type (WT) Balb/c mice were pur-
chased from Slac Laboratory Animal Company. KO
mice were crossed with WT mice to get the heterozy-
gous mice, then the heterozygous mice were crossed
with each other to get the KO mice and WT mice.
A2AR homozygous KO mice and WT Balb/c mice were
bred at the Laboratory Animal Centre of Wenzhou
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Medical University. Homozygous (A2AR−/−: n = 24)
and the corresponding wild-type (A2AR+/+: n = 24)
mice (male, 6–8 weeks old, and weight 17–20 g) were
used in this study. Animal housing and experimental
protocols were approved by the Animal Ethical Committee
of Wenzhou Medical University. The mice were housed
in a specific pathogen-free room with 12 h light/dark
cycle, controlled temperature (23 ± 2 °C) and humidity
(60 ± 10 %). Mice were free access to food and water. All
procedures of our experiments were in the guide for the
Care and Use of Laboratory Animals published by the
US National Institute of Health. Our study also adhered
to the ARRIVE guidelines.
Experimental protocols
The mice were randomly divided into six groups (8
mice/group): WT normal control group (WN), WT
BLM model group (WM), WT baicalin group (WB),
A2aR KO normal control group (AN), A2aR KO BLM
model group (AM), A2aR KO baicalin group (AB). Mice
were anesthetized with 1 % sodium pentobarbital
(50 mg/kg) by intraperitoneal injection. Then, 5U/kg of
bleomycin in sterile 0.9 % NaCl was intratracheally
injected into the mice of WM, WB, AM and AB groups
to induce pulmonary fibrosis [27]. The mice of WN and
AN groups were given the same volume of sterile saline
instead of BLM. From day 1 after intratracheal injection,
daily intraperitoneal injection of baicalin (120 mg/kg)
was administered to the mice in WB and AB groups.
The mice in other groups received sterile saline with di-
methyl sulfoxide. The DMSO was used to dissolve the
baicalin, and the concentration of DMSO was diluted by
sterile saline to 0.1 % in the control and drug-containing
solution. Each group was given 0.0005 ml DMSO per
day. Their lung tissues and serum were harvested after
being scarified on the 28th day.
Measurement of lung coefficient and hydroxyproline
(HYP)
The body weight of mice was measured before being
sacrificed. After sacrificing the mice, the lung was ex-
cised from body and washed with PBS, then measured
weight. The severity of lung injury was assessed by
counting lung coefficient (lung weight (mg)/body weight
(g) Ratio). The levels of HYP reflected the collagen con-
tent and were determined by hydroxyproline (HYP)
assay kits according to the manufacturer’s instructions.
The absorbance of each well was read at 550 nm. The
results were calculated by using the standard formula of
hydroxyproline.
Histopathologic and immunohistochemical staining
The lower lobe of the right lung was fixed in 4 % para-
formaldehyde overnight, dehydrated in a graded ethanol
series, then embedded in paraffin, and cut to 5um thick.
Hematoxylin and eosin (H&E) staining, Masson’s tri-
chrome staining and immunohistostaining were per-
formed on 5 um-thick paraffin-embedded sections. The
primary antibodies used for immunohistochemistry:
anti-TGF-β1 (diluted 1:50 with PBS), anti-p-ERK1/2
(diluted 1:400 with PBS), anti-A2aR (diluted 1:200 with
PBS). The level of histopathological changes and positive
stained area in pulmonary was observed by a light
microscope. 5 different fields under magnification of
400× were chosen randomly from each section and
manufactured one sections for each mice, 8 mice for
each group. There were 40 fields for each group. Image-
Pro Plus 6.0 (Media Cybernetics, USA) was used to
measure the integrated optical density (IOD) of positive
stained cells.
Ultrastructural examination of interstitial tissues of lung
The sample (1 mm3) was taken from the right lower lung
peripheral tissue, fixed in 2.5 % glutaraldehyde and 1 % os-
mium tetroxide, dehydrated with acetone, and then em-
bedded in EPON 812. The fixed tissue pieces were cut
into ultrathin sections by LKB-V-type ultramicrotome.
The thin sections were stained with uranyl acetate and
lead citrate, and then examined under the transmission
electron microscopy (H-7500, Hitachi, Japan).
Cytokine assay
Concentration of TGF-β1 in serum was measured by
ELISA kits according to the manufacturer’s instructions.
The optical density of each sample was read at 450 nm.
The results were calculated by using the linear regression
equation of standard curve.
Western blotting analysis
The lung tissues were homogenised in RIPA lysis buffer
containing PMSF. Then the homogenates were centri-
fuged at 12,000 rpm for 30 min at 4 °C. The superna-
tants containing total protein were collected. The
protein concentration was determined by the BCA pro-
tein assay. Equal amounts of proteins (20 μg) per lane
were separated by 12 % sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAGE) and blotted to polyvi-
nylidene difluoride (PVDF) membranes, then the mem-
branes were blocked for 1 h in 5 % nonfat milk and
incubated overnight at 4 °C with primary antibodies
against TGF-β1(1:500), ERK1/2(1:1000), phospho-
ERK1/2(1:2000), A2aR(1:1000) and GAPDH(1:5000),
respectively, followed by the peroxidase conjugated
goat anti-rabbit or anti-mouse IgG(1:10,000) for 1 h.
Subsequently, Peroxidase labeling was visualized via
enhanced chemiluminescence (ECL) reagents. Images
were detected and analysed by Image Lab program
(Bio-Rad Laboratories, Hercules, CA, USA).
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Statistical analysis
The data were analysed by using SPSS software version
20.0 (IBM, Somers, NY, USA) and expressed as the
mean ± standard deviation (SD). The comparison be-
tween 2 groups was analyzed by Student’s t-test. The
comparison among more than 2 groups was analyzed by
one-way ANOVA, followed by post hoc comparison with
LSD test (equal variances assumed) or Dunnett’s T3 test
(equal variances not assumed). Values of P < 0.05 were
considered to be statistically significant.
Results
A2aR and baicalin reduced the lung coefficient and HYP
of the BLM mouse model
As shown in Fig. 1a, the lung coefficien of model groups
elevated significantly compared with the control groups
in WM and AM groups (p < 0.01 and p < 0.01, resp), and
significantly decreased after baicalin treatment in WB
and AB groups (p < 0.01 and p < 0.05, resp). Besides, the
lung coefficien was respectively higher in AN, AM, AB
groups than in WN, WM, WB groups (p < 0.01, p < 0.05,
and p < 0.01, resp). Figure 1b showed that the HYP con-
tents increased significantly after BLM administration in
WM and AM groups (p < 0.01 and p < 0.01, resp), and
significantly reduced by baicalin in WB and AB groups
(p < 0.05 and p < 0.05, resp). Similarly, the content of
HYP in AM and AB groups was obviously higher, com-
pared with WM and WB groups (p < 0.05 and p < 0.05,
resp). However, there was no significant difference be-
tween AN group and WN group.
A2aR and baicalin alleviated pulmonary histopathological
changes in the BLM mouse model
HE and Masson’s staining were performed to observe
the histopathological changes in lung. The lung of mice
in WN group showed no abnormal histological changes
(Fig. 2). However, in AN group, the HE staining in the
sections revealed the slight thickening of alveolar
septum, and the Masson’s staining showed that there
was a small amount of collagen depositing in pulmonary
interstitial. The model groups indicated significant
pathological changes in sections with HE staining, e.g.
widespread interalveolar septum thickness, inflammatory
cells infiltration and alveolar hemorrhage; and the
Masson’s staining indicated an abundance of collagen
deposition. Besides, the degree of fibrosis in AM group
is the most serious. Baicalin could attenuate the patho-
logical changes induced by BLM, and the effect on WT
mice is better than on KO mice.
A2aR and baicalin ameliorated pulmonary ultrastructural
changes in the BLM mouse model
The transmission electron microscopy was used to ob-
serve the pulmonary ultrastructural changes. Similar with
the results of the pathological sections, there was little
change in ultrastructure of WN group, and the interalveo-
lar septum was normal, the junction between cells was
tight. Compared with the WN group, there were slight
karyopyknosis and vacuolations in the type I alveolar epi-
thelial cells of the AN group (Fig. 3). After BLM adminis-
tration, the WT model groups showed that type II
alveolar epithelial cell became hyperplastic, with produc-
tion of numerous vacuolations and lamellar bodies, depos-
ition of collagen fibers and the swelling of organelles.
Moreover, the AM group indicated the highest number of
collagen fibers in the interalveolar septum, with markedly
condensation of chromatin, disordered cell structure and
deformed basement membrane. After the treatment of
baicalin, the ultrastructural improvement of WB group
was the most significant, the structure of type I alveolar
epithelial cells was complete, and there was no obvious
collagen fibers depositing in interalveolar septum. How-
ever, the effect of baicalin on KO mice was worse than on
WT mice. The number of lamellar bodies in type II alveo-
lar epithelial cells decreased, but there were still vacuola-
tions and collagen fibers in cells.
Fig. 1 A2aR and baicalin reduced the lung coefficient and HYP of the BLM mouse model. a Comparison lung coefficient in each group. b
Comparison HYP content of mice in each group. Data were expressed as mean ± standard deviation (SD), ** p < 0.01 vs control group, ## p < 0.01
vs model group, # p < 0.05 vs model group, ++ p < 0.01 between WT and KO groups, + p < 0.05 between WT and KO groups; n = 8
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Fig. 2 A2aR and baicalin alleviated pulmonary histopathological changes in the BLM mouse model. a Images of H&E of pulmonary tissue
sections (light microscopy, ×400). Control groups show the normal interalveolar septum; model groups indicate widespread interalveolar septum
thickness; baicalin groups exhibit reduced tissue injury. And the histopathological changes in KO mice are more obvious. b Images of Masson’s
trichrome staining of pulmonary tissue sections (light microscopy, ×400). Control groups show no obvious collagen fibers deposition; model
groups indicate an abundance of collagen deposition (blue-stained); baicalin groups exhibit reduced collagen fibers deposition. The deposition of
collagen fibers in KO mice is more obvious. Scale bars represent 100 μm
Fig. 3 A2aR and baicalin ameliorated pulmonary ultrastructural changes in the BLM mouse model. The ultrathin sections were observed under a
Hitachi H-7500 transmission electron microscopy (10,000×). Control groups show little change in ultrastructure; model groups indicate destruction
of alveolar epithelial cells and deposition of collagen fibers; baicalin groups exhibit obvious ultrastructural improvement. The ultrastructure of KO
mice is more severely damaged. Scale bars represent 1 μm
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A2aR and baicalin attenuated TGF-β1 expression in the
BLM mouse model
We measured the expression of TGF-β1 in serum and
lung by ELISA, immunohistochemical staining and
Western blotting. Examination by ELISA revealed that
TGF-β1 in serum was markedly upregulated in the
model groups (p < 0.01 and p < 0.01, resp). On the
contrary, baicalin efficiently reduced TGF-β1 expres-
sion (p < 0.01 and p < 0.01, resp) (Fig. 4c). Compared
with WT mice, the concentration of TGF-β1 in KO
mice was higher (p < 0.05, p < 0.05, and p < 0.05, resp).
Consistent with the ELISA, the results of immunohisto-
chemical staining and western blot also indicated the
differences in TGF-β1 expression in WT and A2aR KO
mice (Fig. 4a, b, d and e).
A2aR and baicalin attenuated ERK1/2 phosphorylation in
the BLM mouse model
In both WT and KO mice, western blot indicated an
obvious increase of phospho-ERK1/2 in model groups
(p < 0.01 and p < 0.01, resp) and a remarked reduction
of phospho-ERK1/2 in baicalin groups (p < 0.05 and
p < 0.01, resp), and there were significant differences
between the WN, WM, WB groups and AN, AM, AB
groups (p < 0.05, p < 0.05, and p < 0.05, resp) (Fig. 5d, e).
But the total ERK1/2 was not significant in each
Fig. 4 A2aR and baicalin attenuated TGF-β1 expression in the BLM mouse model. a Images of TGF-β1 immunohistochemistry in lung tissue
sections. Magnification ×400, scale bars represent 100 μm. b Quantitative analysis of TGF-β1 protein by immunohistochemistry. c TGF-β1
content (pg/ml) of serum (ELISA) (n = 8). d Images of TGF-β1 in lung homogenate (western blot). e Quantitative analysis of TGF-β1 in lung by
western blot. GAPDH was used as internal control (n = 3). Data were expressed as mean ± SD. ** p < 0.01 vs control group, * p < 0.05 vs control
group, ## p < 0.01 vs model group, # p < 0.05 vs model group, ++ p < 0.01 between WT and KO groups, + p < 0.05 between WT and
KO groups
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group (Fig. 5f, g). The ratio of phospho-ERK1/2 to
total ERK1/2 accorded with the phospho-ERK1/2
(Fig. 5c). The immunohistochemistry of phospho-
ERK1/2 revealed the same result, except that there
was no significant difference between normal groups
(Fig. 5a, b).
Baicalin increased A2aR expressions in the BLM mouse
model
We tested the effects of baicalin on A2aR protein
expressions of WT mice after bleomycin administration
by immunohistochemical staining and western blotting,
and the results suggested bleomycin increased A2aR
Fig. 5 A2aR and baicalin attenuated ERK1/2 phosphorylation in the BLM mouse model. a Images of p-ERK1/2 immunohistochemistry in lung
tissue sections. Magnification ×400, scale bars represent 100 μm. b Quantitative analysis of p-ERK1/2 protein by immunohistochemistry. c The
protein expression ratios of phospho-ERK1/2 to total-ERK1/2. d Images of p-ERK1/2 in lung homogenate (western blot). e Quantitative analysis of
p-ERK1/2 in lung by western blot. f Images of total-ERK1/2 in lung homogenate (western blot). g Quantitative analysis of total-ERK1/2 in lung by
western blot. GAPDH was used as internal control (n = 3). Data were expressed as mean ± SD. ** p < 0.01 vs control group, ## p < 0.01 vs model
group, # p < 0.05 vs model group, ++ p < 0.01 between WT and KO groups, + p < 0.05 between WT and KO groups
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expression in WM group compared with WN group
(p < 0.01, and p < 0.01, resp). Besides, baicalin treatment
enhanced A2aR expression in WB group (p < 0.01, and
p < 0.05, resp) (Fig. 6a, b, c).
Discussion
Jia et al. have already found baicalin could attenuate
bleomycin-induced pulmonary fibrosis in rats [26]. But
in our study, we proved that baicalin alleviated pulmon-
ary fibrosis via A2aR related TGF-β1 induced ERK1/2
signaling pathway.
IPF is a progressive and terminal disease with high
mortality. Bleomycin-induced lung fibrosis animal model
is widely used to investigate IPF, which is characterized
by the destruction of the lung architecture and collagen
deposition in the lungs [28]. Thus, the increase in lung
coefficient and HYP as well as the obvious changes in
pulmonary histopathology and ultrastructure of model
groups indicated success in establishing the model of
IPF.
Although the mechanisms underlying pulmonary fi-
brosis remains elusive, chronic persistent inflammation
and epithelial mesenchymal transition (EMT) have been
considered the two important pathogenic events of IPF
[29]. Therefore, inhibition of inflammation or EMT may
be an efficient therapeutic strategy for IPF. Adenosine,
an endogenous intracellular purine nucleoside, is at low
concentrations extracellularly under normal conditions,
but released increasingly by cells during inflammation
and tissue destruction [8, 30]. It regulates cellular func-
tion by interacting with a family of 4G protein–coupled
receptors, A1R, A2aR, A2bR, and A3R [31]. It is well
known that A2aR is expressed on macrophages, den-
dritic cells, T cells, B cells, epithelial cells and considered
as a novel endogenous modulator affecting the inflam-
mation process and tissue repair [32]. Zhou detected
Fig. 6 Baicalin increased A2aR expressions in the BLM mouse model. a Images of A2aR in lung homogenate (western blot). b Quantitative
analysis of A2aR in lung by western blot. GAPDH was used as internal control (n = 3). c Images of A2aR immunohistochemistry in lung tissue
sections. Magnification ×400, scale bars represent 100 μm. d Quantitative analysis of A2aR protein by immunohistochemistry. e The signaling
pathway was demonstrated in this experiment. Data were expressed as mean ± SD. ** p < 0.01 vs control group, ## p < 0.01 vs model group,
# p < 0.05 vs model group
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that A2aR was down-regulated in severe IPF patients
[33], but in our study, an increased A2aR expression was
determined in lung tissue in BLM-treated WT mice,
which may be a provisional compensatory increase and
related to the course of IPF, we will clarify the detailed
change of A2aR in the future. Scheibner KA et al. found
A2aR-null mice are more susceptible to bleomycin-
induced lung injury [12], demonstrated that A2aR plays
an important role in inhibiting pulmonary fibrosis of
mice. But Scheibner’s study only observed histopatho-
logic changes of lung tissue on 7 days after the mice
were treated with BLM, at that time, pulmonary fibrosis
was not so obvious. In our study, lung coefficient and
HYP was significantly higher in KO mice than in WT
mice. The structure of lung, which was observed under
the light microscope and transmission electron micros-
copy, have been found changed more obviously in KO
mice than in WT mice. All these findings proved that
the degree of pulmonary fibrosis in A2aR−/− mice was
more serious and A2aR played a protective role in IPF,
which is consistent with other studies. Noteworthy, the
difference in lung coefficient between WN group and
AN group was significance, and HE and Masson’s stain-
ing of AN group showed slight fibrosis.while there was
no significant difference in HYP content between the
two groups. We infer that it is because the deficiency of
A2aR would weaken the body’s resistance to external
stimulation (saline), thus causing damage to lung which
led to slight fibrosis rather than obvious pulmonary
fibrosis.
EMT is a hot research topic at present. Many studies
have indicated that EMT has a close relationship with
pulmonary fibrosis. In the process of EMT, type II alveo-
lar epithelial cell is considered to be the primary cell
which repairs alveolar epithelium after injury, and it can
transform into type I alveolar epithelial cell, fibroblast
and myofibroblasts after injury. Finally the deposition of
ECM leads to the development of IPF [34–36]. TGF-β1
is thought to drive the cardinal processes to the initi-
ation and progression of lung fibrosis, including inflam-
matory response, epithelial cell apoptosis, EMT,
fibroblast proliferation, and collagen deposition [37]. In
our model, the immunohistochemistry and western ana-
lysis shown the expression of TGF-β1 increased to vary-
ing degrees after baicalin administration to both WT
and KO mice.
Mitogen-activated protein kinase (MAPK) superfamily
(ERK, p38, and JNK) is an important family of enzymes
associated with cell membrane receptors and regulative
targets, and ERK1/2 are members of the MAPK family.
ERK1/2 signaling pathway is the most thoroughly stud-
ied signal transduction pathways. They can be activated
by a series of cell growth factors and become phospho-
ERK1/2, then transmits extracellular signals from the
cell surface to the nucleus, which contributes to the pro-
liferation and differentiation of cells, such as prolifera-
tion of lung fibroblasts and production of extracellular
matrix (ECM). Researchers have proved that the ECM
process may be achieved partly via the activation of
TGF-β pathway, involving the TGF-β1-induced MAPK
pathway [38, 39]. Taken together, the similarly upregula-
tion of the protein level of pulmonary ERK1/2 in BLM-
treated mice observed in this study may be explained by
the above mechanism. However, there is no direct report
about the relationship between A2aR and TGF-β1-
induced ERK1/2 pathway in pulmonary fibrosis. Our
data shown a significantly increased protein expression
of TGF-β1 and phospho-ERK1/2 in KO model mice,
which illustrated that A2aR could down-regulate the
TGF-β1-induced ERK1/2 pathway in lung fibrosis for
the first time. From another point of view, these results
confirmed the protective effect of A2aR on pulmonary
fibrosis. It is interesting to note that in the western blot
graph of p-ERK1/2, the increase degree of p-ERK1 in
WM group seems higher than that of p-ERK2, but no
obvious difference was found in the rest of groups be-
tween p-ERK1 and p-ERK2. We speculate that there are
two probable reasons: the first reason is that it was
caused by the differences between individual mice; the
second reason is that the pathway of ERK1 was indeed
more associated with IPF than ERK2. Though the under-
lying mechanism is still unclear, we will perform further
researches to clarify it.
A variety of clinical methods are used to treat IPF,
such as corticosteroids, azathioprine, pirfenidone, anti-
coagulants, tyrosine kinase inhibitors and N-acetyl-
cysteine [40]. Corticosteroids has been widely used as
the prescribed treatment of IPF in clinic for a long time,
but the efficacy of this treatment is not satisfied and its
side effects are severe [41, 42]. And the effect of other
drugs was not significant. So it is critical and urgent to
discover a drug that has a good effect and few side ef-
fects. Baicalin, a pharmacologically bioactive compo-
nents purified from Scutellaria baicalensis, possesses
diverse pharmacological activities. Several studies dem-
onstrated that baicalin exerted a therapeutic effect on
hepatic fibrosis [43, 44]. Gong LK et al. discovered Feitai
was useful in the treatment of pulmonary fibrosis, and
Feitai is a Chinese composite formula comprising
Scutellaria baicalensis [45]. Baicalin was also reported
to inhibit the expression of TGF-β1 in pulmonary ar-
terial hypertension [46]. However, whether baicalin
would inhibit TGF-β1-induced MAPK pathway via ad-
enosine A2a receptor has not been investigated. In our
experiment, baicalin was found to be effective in redu-
cing the expression of TGF-β1 and phospho-ERK1/2 in
pulmonary fibrosis, thus partially inhibiting epithelial
mesenchymal transition (EMT), which may be a critical
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mechanism via which baicalin protects mice with PF.
Moreover, A2aR expressed the highest after baicalin
treatment, suggesting that baicalin exerted effects on
PF through A2aR. Consistently, this study showed that
baicalin activated A2aR and the activation of A2aR sup-
pressed TGF-β1 activation, which down-regulated ERK1/2
expression (Fig. 6d).
Conclusions
In summary, baicalin is effective in inhibiting histopatho-
logical and ultrastructural damages in BLM-induced PF
partially via enhancing A2aR and then down-regulating
TGF-β1 induced ERK1/2 signaling pathway. This will pro-
vide a significant insight of the protective effects of baica-
lin in PF and the underlying mechanisms may become a
theoretical basis for the use of baicalin in themanagement
of clinical PF.
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